Previous 10 | Next 10 |
home / stock / phmmf / phmmf news
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Pharmamar S.A. (PHMMF) is expected to report for quarter end 2023-12-31
2023-03-04 14:06:02 ET Pharma Mar, S.A. (PHMMF) Q4 2022 Earnings Conference Call March 01, 2023 07:00 AM ET Company Participants Jose Luis - Head, Investor Relations & Capital Markets Maria Luisa de Francia - Chief Financial Officer Luis Mora - Managing Direc...
Pharma Mar, S.A. (PHMMF) Q4 2021 Results Conference Call March 01, 2022 07:00 AM ET Company Participants Jose Luis Moreno - Head, IR and Capital Markets Luis Mora - Managing Director Maria Luisa de Francia - CFO Conference Call Participants Christian Glennie - Stifel Alvaro Lenze - Alantra Jo...
Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants - The final results of the APLICOV-PC study (Phase I-II), which were initially released last May ...
The following slide deck was published by Pharma Mar, S.A. in conjunction with this Read more ...
- Lurbinectedin is approved under "Accelerated Approval" based on overall response rate and duration of response demonstrated in an open-label, monotherapy clinical trial. - The anti-tumor compound lurbinectedin will be marketed under the brand name Zepzelca ™ . - Lurbinected...
MADRID , April 28, 2020 /PRNewswire/ -- PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin ® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AE...
Pharma Mar SA (PHMMF) Conference Call to Discuss Jazz Pharmaceuticals License Agreement for Lurbinectedin in the U.S. January 9, 2020 8:00 AM ET Company Participants José Luis Moreno – Director of Investor Relations & Capital Markets Pascal Besman – U.S. Chie...
MADRID , Oct. 19, 2018 /PRNewswire/ -- Sylentis, PharmaMar Group (MCE: PHM), has announced today that it has reached its target of recruiting 300 patients for the Phase III trial "HELIX" [1] for the treatment of the signs and symptoms of dry eye disease. PharmaMar estimate tha...
News, Short Squeeze, Breakout and More Instantly...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...
Ebix Inc. (EBIXQ) is expected to report for Q1 2024 Amesite Inc. (AMST) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.68 for Q1 2025 Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A) (WDH) is expected to repo...
TDCX Inc. American Depositary Shares each representing one Class A (TDCX) is expected to report for Q1 2024 nCino Inc. (NCNO) is expected to report $0 for Q1 2025 SK Telecom Co. Ltd. (SKM) is expected to report for Q1 2024 Redeia Corporacion S.A. ADR (RDEIY) is expected to report for ...